MAU868

BIOLOGICAL2 trials

Sponsors

Novartis Pharmaceuticals, Vera Therapeutics, Inc.

Conditions

BK Virus InfectionBK Virus Nephropathy

Phase 2

Determine the Safety, Tolerability, and Efficacy of MAU868 for the Prevention of BK Virus Infection in Kidney Transplant Recipients

WithdrawnNCT03456999

Novartis PharmaceuticalsBK Virus Nephropathy

Start: 2018-10-15End: 2020-11-16Updated: 2018-12-13

A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients

CompletedNCT04294472

Vera Therapeutics, Inc.BK Virus Infection

Start: 2020-08-05End: 2022-02-10Updated: 2023-06-07